Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.
Martina GambatoLaetitia CaniniSabela LensFrederik GrawElena PerpiñanMaria-Carlota LondoñoSusan L UprichardZoe MariñoEnric ReverterConcepcio BartresPatricia GonzálezAnna PlaJosep CostaPatrizia BurraScott J CotlerXavier FornsHarel DahariPublished in: Liver international : official journal of the International Association for the Study of the Liver (2018)
The study provides insights into HCV dynamics during DAAs therapy in patients with compensated and decompensated cirrhosis. Viral kinetics modelling suggests that treatment duration may be optimized in patients with compensated cirrhosis.